AGY — Allergy Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual income statement for Allergy Therapeutics, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.

	2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	78.2	84.3	72.8	59.6	55.2
Cost of Revenue
Gross Profit	58	62.2	49.5	33.2	29.7
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	69.9	80.3	85	99.2	90.5
Operating Profit	8.31	4.03	-12.2	-39.7	-35.3
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8.07	3.66	-12.7	-41.8	-39.2
Provision for Income Taxes
Net Income After Taxes	7.06	2.89	-13.8	-43.1	-40.2
Net Income Before Extraordinary Items
Net Income	7.06	2.89	-13.8	-43.1	-40.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7.06	2.89	-13.8	-43.1	-40.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.005	0.002	-0.01	-0.027	-0.011